BSE Live
Mar 30, 16:01Prev. Close
1557.20
Open Price
1556.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 30, 15:58Prev. Close
1558.40
Open Price
1548.00
Bid Price (Qty.)
1504.80 (83)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Caplin Point Laboratories (in Rs. Cr.) | Jun 10 | Jun 09 | Jun 08 | Mar 07 | Jun 06 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 2.21 | 1.47 | 0.80 | 1.11 | 1.75 | |
| Diluted EPS (Rs.) | 2.21 | 1.47 | 0.80 | 1.11 | 1.75 | |
| Cash EPS (Rs.) | 3.59 | 2.80 | 2.72 | 2.21 | 2.15 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 14.36 | 13.32 | 12.15 | 10.75 | 9.64 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 16.83 | 15.79 | 15.02 | 10.75 | 9.64 | |
| Dividend / Share(Rs.) | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 39.96 | 40.32 | 48.53 | 29.52 | 23.53 | |
| PBDIT/Share (Rs.) | 4.04 | 3.64 | 3.23 | 3.28 | 2.50 | |
| PBIT/Share (Rs.) | 2.66 | 2.31 | 1.34 | 2.25 | 2.17 | |
| PBT/Share (Rs.) | 2.10 | 1.68 | 0.70 | 1.76 | 1.98 | |
| Net Profit/Share (Rs.) | 2.21 | 1.47 | 0.80 | 1.11 | 1.75 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 10.11 | 9.02 | 6.66 | 11.12 | 10.63 | |
| PBIT Margin (%) | 6.64 | 5.72 | 2.75 | 7.61 | 9.24 | |
| PBT Margin (%) | 5.26 | 4.15 | 1.43 | 5.97 | 8.42 | |
| Net Profit Margin (%) | 5.51 | 3.65 | 1.63 | 3.76 | 7.42 | |
| Return on Networth / Equity (%) | 15.35 | 11.05 | 6.55 | 10.32 | 18.10 | |
| Return on Capital Employed (%) | 12.37 | 8.75 | 4.51 | 9.79 | 13.97 | |
| Return on Assets (%) | 5.50 | 3.62 | 1.85 | 3.80 | 5.43 | |
| Total Debt/Equity (X) | 0.48 | 0.43 | 0.69 | 0.49 | 0.78 | |
| Asset Turnover Ratio (%) | 99.78 | 99.34 | 113.08 | 101.16 | 73.22 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.16 | 1.18 | 1.16 | 1.04 | 1.09 | |
| Quick Ratio (X) | 1.03 | 0.96 | 0.97 | 0.88 | 0.88 | |
| Inventory Turnover Ratio (X) | 14.53 | 8.00 | 10.16 | 10.58 | 5.84 | |
| Dividend Payout Ratio (NP) (%) | 45.35 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 27.85 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 54.65 | 0.00 | 0.00 | 100.00 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 72.15 | 0.00 | 0.00 | 100.00 | 100.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 16.84 | 5.02 | 11.46 | 16.62 | 12.70 | |
| EV/Net Operating Revenue (X) | 0.28 | 0.08 | 0.18 | 0.43 | 0.41 | |
| EV/EBITDA (X) | 2.76 | 0.91 | 2.72 | 3.89 | 3.90 | |
| MarketCap/Net Operating Revenue (X) | 0.35 | 0.22 | 0.17 | 0.35 | 0.29 | |
| Retention Ratios (%) | 54.64 | 0.00 | 0.00 | 100.00 | 100.00 | |
| Price/BV (X) | 0.97 | 0.66 | 0.68 | 0.96 | 0.70 | |
| Price/Net Operating Revenue | 0.35 | 0.22 | 0.17 | 0.35 | 0.29 | |
| Earnings Yield | 0.16 | 0.17 | 0.10 | 0.11 | 0.26 |
10.02.2026
Caplin Labs Consolidated December 2025 Net Sales at Rs 542.77 crore, up 10.1% Y-o-Y
09.02.2026
Caplin Labs Standalone December 2025 Net Sales at Rs 189.22 crore, up 2.15% Y-o-Y
12.11.2025
Caplin Labs Standalone September 2025 Net Sales at Rs 175.18 crore, down 15.75% Y-o-Y
05.11.2025
Caplin Labs Consolidated September 2025 Net Sales at Rs 534.04 crore, up 10.54% Y-o-Y
30.03.2026
Wockhardt novel antibiotic Zaynich gets thumbs-up from CDSCO expert panel
30.03.2026
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth